Related references
Note: Only part of the references are listed.SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
Corey A. Siegel et al.
GUT (2021)
Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease
Michael D. Kappelman et al.
GASTROENTEROLOGY (2021)
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
Serre-Yu Wong et al.
GASTROENTEROLOGY (2021)
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Nicholas A. Kennedy et al.
GUT (2021)
Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods
Emma English et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Ugur Sahin et al.
NATURE (2021)
Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays
Ahmed Ismail et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2021)
Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test
Silvia Meschi et al.
JOURNAL OF CLINICAL VIROLOGY (2020)
Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce
F. Magro et al.
JOURNAL OF CROHNS & COLITIS (2020)